Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P49589
UPID:
SYCC_HUMAN
Alternative names:
Cysteinyl-tRNA synthetase
Alternative UPACC:
P49589; Q53XI8; Q5HYE4; Q9HD24; Q9HD25
Background:
Cysteine--tRNA ligase, cytoplasmic, also known as Cysteinyl-tRNA synthetase, plays a crucial role in protein synthesis by catalyzing the ATP-dependent ligation of cysteine to tRNA(Cys). This enzyme ensures the accurate translation of genetic information into functional proteins, a fundamental process in cellular biology.
Therapeutic significance:
The enzyme's mutation is linked to Microcephaly, developmental delay, and brittle hair syndrome, an autosomal recessive disorder. This association highlights the enzyme's critical role in human development and disease, suggesting that targeting Cysteine--tRNA ligase could offer new avenues for therapeutic intervention in genetic disorders.